Actively Recruiting
Phase IIa Study to Assess the Effectiveness and Safety of HP515 Tablets for Adults With Non-Alcoholic Fatty Liver Disease
Led by Hinova Pharmaceuticals Inc. · Updated on 2025-12-29
80
Participants Needed
2
Research Sites
20 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of HP515 tablets in people with non-alcoholic fatty liver disease NAFLD. This Phase IIa clinical trial aims to study the efficacy, safety, pharmacokinetics how the drug moves through the body, and pharmacodynamics how the drug affects the body of HP515. The study also explores how HP515 impacts specific biological markers related to this liver condition. Participants undergo a screening period of 4 weeks, followed by a 12-week treatment phase where they receive different doses of HP515 or a placebo. They are randomly assigned to groups based on body weight, with doses ranging from 40 mg to 60 mg daily. During treatment, participants take tablets once daily and undergo various tests, including blood sampling for drug levels and imaging exams like MRI and FibroScan to monitor liver fat and health. After treatment, a 4-week safety follow-up period is conducted. Throughout the study, participants have multiple visits for assessments including liver imaging at screening, during treatment, and at early withdrawal if applicable. Blood samples are collected fasting before dosing at several time points to study drug behavior. Researchers track changes in liver fat using MRI-PDFF and monitor safety through adverse event reports. The total duration for participants is up to 16 weeks, including screening, treatment, and safety follow-up.
CONDITIONS
Brief Title
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
Research Team
Y
Yang Ming YM Chief physician
W
Wei WL chief physician
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here